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Background: Macroautophagy is an evolutionarily conserved mechanism for bulk intracellular degradation of
proteins and organelles. Pathological studies have implicated macroautophagy defects in human
neurodegenerative disorders of aging including Alzheimer’s disease and tauopathies. Neuronal deficiency of
macroautophagy throughout mouse embryonic development results in neurodevelopmental defects and early
postnatal mortality. However, the role of macroautophagy in mature CNS neurons, and the relationship with human
disease neuropathology, remains unclear. Here we describe mice deficient in an essential macroautophagy
component, Atg7, specifically within postnatal CNS neurons.
Results: Postnatal forebrain-specific Atg7 conditional knockout (cKO) mice displayed age-dependent
neurodegeneration and ubiquitin- and p62-positive inclusions. Phosphorylated tau was significantly accumulated in
Atg7 cKO brains, but neurofibrillary tangles that typify end-stage human tauopathy were not apparent. A major tau
kinase, glycogen synthase kinase 3β (GSK3β), was also accumulated in Atg7 cKO brains. Chronic pharmacological
inhibition of tau phosphorylation, or genetic deletion of tau, significantly rescued Atg7-deficiency-mediated
neurodegeneration, but did not suppress inclusion formation.
Conclusions: These data elucidate a role for macroautophagy in the long-term survival and physiological function
of adult CNS neurons. Neurodegeneration in the context of macroautophagy deficiency is mediated through a
phospho-tau pathway.Background
The primary etiologies of neurodegenerative disorders,
including Alzheimer’s disease (AD), frontotemporal de-
mentia (FTD) and Parkinson’s disease (PD), remain
largely unknown, but common pathological features sug-
gest a role for altered protein degradation. For instance,
proteinaceous intracellular inclusions composed in part
of aggregated α-synuclein protein, termed Lewy bodies,
typify PD brain pathology, whereas neurofibrillary tan-
gles (NFT) and Pick bodies containing phosphorylated
tau protein are commonly found in the context of taupa-
thies such as AD and FTD. Rare, inherited familial forms
of neurodegenerative diseases [1] are caused by* Correspondence: aa900@columbia.edu
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reproduction in any medium, provided the ormutations in genes encoding these accumulated pro-
teins, such as α-synuclein [2,3] in PD and tau in FTD,
but the vast majority of patients do not harbor known
mutations. Thus, it has been hypothesized that in these
‘sporadic’ cases, pathological inclusions may reflect
broadly defective protein degradation through mechan-
isms such as the ubiquitin-proteasome system (UPS) [4]
and macroautophagy [5,6]. The latter is of particular
interest because of its apparent role in the degradation
of protein aggregates and inclusions [7].
Macroautophagy is a pathway of bulk cytoplasmic pro-
tein and organelle degradation characterized by double-
membrane vesicles that engulf cargo and target it to
lysosomes for degradation [8]. The pathway is typically
induced in the context of starvation or other stressors.
Defects in the macroautophagy process may theoretically
occur at a variety of steps, from the initial formation of atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fusion of mature autophagosomes with the lysosomal
compartment [9]. Macroautophagy defects have been
well described on pathological analyses of brain sections
from patients with a variety of neurodegenerative disor-
ders, including AD, PD and FTD [5,10]. Furthermore,
inherited genetic forms of neurodegeneration are asso-
ciated with mutations in the macroautophagy-lysosomal
pathway [11,12]. Finally, as macroautophagy dysfunction
is a well-documented feature of aging, it has been impli-
cated in the age-dependent nature of the major neurode-
generative disorders [5,9,10].
Genetically altered mice that are deficient in essential
macroautophagy pathway components, Atg5 or Atg7,
throughout neural development, display reduced neur-
onal survival and harbor ubiquitin-positive inclusions in
the cell soma [13-16]. But surprisingly, prevention of in-
clusion formation in the context of Atg7-deficiency by a
second genetic ablation of p62, which encodes an
ubiquitin-binding protein associated with autophago-
somes, does not suppress neurodegeneration, arguing
against a toxic role for inclusions [17]. Thus, the mechan-
ism of neuronal loss with macroautophagy deficiency, and
how this relates to neurodegeneration, remains unclear.
Here we generated conditional Atg7-deficient mice
specifically within mature CNS neurons. Atg7-deficient
neurons were defective in the initiation of macroauto-
phagy, and displayed a progressive degeneration with
prominent inclusions that harbor ubiquitin, p62, phos-
phorylated tau and GSK3β. The mutant mice exhibited
behavioral deficits consistent with the pathological
changes. Furthermore, pharmacological or genetic sup-
pression of tau phosphorylation effectively inhibited neu-
rodegeneration in the context of Atg7-deficiency in vivo.
Results
Slowly progressive degeneration of postnatal
Atg7-deficient hippocampal CA1 neurons
Genetically altered mice that are deficient in an essential
component of the macroautophagy machinery, Atg7
[18], specifically within mature forebrain neurons, were
generated using a Cre-loxP strategy [19]. Briefly, we
interbred mice that express bacterial Cre recombinase
(CRE) under the control of the CamKIIα gene regulatory
sequences (CamK-Cre) [20] with Atg7flox/flox mice [19].
CRE expression was limited to CA1 field pyramidal neu-
rons of the hippocampus and glutamatergic neurons
within the cerebral cortex [20], leading to ATG7 loss
and prominent macroautophagy defects including the
accumulations of LC3, GABARAP, GABARAPL1, and
p62 in forebrain specific Atg7 conditional knockout
(CamK-Atg7 cKO) mice (Figure 1a,b). Quantification of
CA1 pyramidal neuron number revealed a significant re-
duction of approximately 25% in CamK-Atg7 cKO miceat 1-year of age, while 3-month-old cKO mice maintained
a normal complement of CA1 neurons (Figure 1c). Con-
sistent with the neurodegenerative process, hippocampal
CA1 neurons of 8-month-old CamK-Atg7 cKO mice
stained positively for cleaved caspase-3 (Figure 1d). In
contrast, neither neuronal loss nor caspase-3 positive sig-
nal was observed in the cerebral cortex of 1-year-old
CamK-Atg7 cKO mice.
Furthermore, numerous ubiquitin-positive inclusions
were apparent in essentially all Atg7-deficient CA1 cell
bodies from 2-month of age, whereas these were never
seen in the control CamK-Atg7 cWT mice (Figure 1e).
These inclusions were stained positive for p62 [17,21],
which is a component of the macroautophagy machinery
pathway (Additional file 1), and further confirmed the
macroautophagy defect in forebrain neurons. In con-
trast, such inclusions were absent from the CA3 neurons
(data not shown). Further analysis by electron micros-
copy revealed that these inclusions were composed of
both filamentous and vesicular elements (Figure 1f ).
We further compared CamK-Atg7 cKO neurodegen-
eration with the effect of Atg7 deficiency in a second
population of mature CNS neurons, midbrain dopamine
(DA) neurons. To this end, we generated animals that
express CRE under the control of the dopamine trans-
porter (Dat) gene regulatory elements, and are homozy-
gous for the floxed Atg7 allele (DatCre/+Atg7flox/flox; Dat-
Atg7 cKO mice rather than CamK-Atg7 cKO mice).
Dat-Atg7 cKO mice displayed a very similar pathological
progression to CamK-Atg7 cKO mice with cytoplasmic
ubiquitin- and p62-positive inclusions, albeit the process
is selective for midbrain DA neurons as expected (Add-
itional file 2c,d). Neurodegeneration progresses appeared
more rapid in the Dat-Atg7 cKO mouse model than the
CamK-Atg7 cKO mouse model (25% midbrain DA
neuron lost at 2-months of age and 38% lost at 4-month;
Additional file 2a,b).
Atg7 deficiency in mouse postnatal forebrain neurons
results in physiological and behavioral deficits
We further examined the physiological and behavioral
consequences of Atg7-deficiency within forebrain neu-
rons. Extracellular recording of field potentials were per-
formed at Schaffer collateral synapses in area CA1 of
acutely prepared hippocampal slices from 3-month-old
male CamK-Atg7 cKO mice and control CamK-Atg7
cWT littermates. CamK-Atg7 cKO mice showed normal
input/output amplitudes in response to single stimuli
(Figure 2a), as well as intact paired-pulse facilitation
(PPF) at a variety of interpulse intervals (Figure 2b).
These findings suggest that there are no gross differ-
ences in synaptic organization or baseline synaptic trans-
mission in the cKO mice at this age. In contrast, early
long-term potentiation (E-LTP) induced by a single
Figure 1 Age-dependent neurodegeneration in forebrain-specific Atg7-deficient mice. (a-b) Impaired macroautophagy in CamK-Atg7 cKO
mouse forebrain tissues including hippocampus and cortex. a, ATG7 protein was significantly reduced in CamK-Atg7 cKO brains. Consistent with
ATG7 change, mammalian Atg8 homologues (LC3, GABARAP and GABARAPL1) and macroautophagy substrate p62 were accumulated in
CamK-Atg7 cKO brains. b, Poly-ubiquitinated proteins were accumulated in both 0.5% TritonX-100-soluble and insoluble fractions of CamK-Atg7
cKO forebrain. These results indicate that macroautophagy is impaired in the forebrains of CamK-Atg7 cKO mice. (c-d) Slow progressive loss of
hippocampal CA1 pyramidal neurons in CamK-Atg7 cKO mice. c, Quantification of CA1 pyramidal neuron number. White bars, CamK-Atg7 cWT.
Black bars, CamK-Atg7 cKO. n = 3 - 4 for each group. **, P < 0.01. d, Pyramidal neurons in the CA1 region of 8-month-old CamK-Atg7 cKO mice
were cleaved caspase-3-positive. Bar, 40 μm. (e) Cytoplasmic inclusions in 6-month-old CamK-Atg7 cKO mice. Ubiquitin-positive (green) inclusions
were present in MAP2-positive (red) hippocampal CA1 neurons of CamK-Atg7 cKO mice, but were never seen in control CamK-Atg7 cWT mice.
Ubiquitin-positive inclusions were also positive for p62 (Additional file 1), as previously. Bar, 10 μm. (f) Electron microscopic analyses of
cytoplasmic inclusions. The dashed squares outline two inclusions in the cytoplasm on neurons of Atg7 cKO mice. At higher magnification,
these inclusions display fibrillar and vesicular components and lack an outer membrane. Inclusions were never observed in control cWT mice. Bar,
500 nm.
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tein synthesis-independent form of synaptic potentiation
- was impaired in CamK-Atg7 cKO slices (Figure 2c). In
contrast, we note that long-term depression was intact
in the cKO mice (data not shown). The relatively select-
ive physiological impairment is unlikely to be secondary
to the limited cell loss.
Next, we assessed forebrain-dependent fear condition-
ing in CamK-Atg7 cKO mice and CamK-Atg7 cWT
mice. CamK-Atg7 cKO mice did not show any increasein the ratio of freezing at their basal level. However,
CamK-Atg7 cKO mice showed a significant impairment
in contextual fear conditioning relative to control
CamK-Atg7 cWT animals (Figure 2d). Furthermore, the
cKO mice showed significant reduced freezing ratio in
cued fear conditioning, whereas the basal freezing
(‘Pre-Test’) was not changed (Figure 2e). Taken together,
these data demonstrate forebrain physiological dysfunc-
tion, consistent with the selective forebrain pathology of
CamK-Atg7 cKO mice.
Figure 2 Physiological and behavioral alterations in forebrain-specific Atg7-deficient mice. (a-c) Forebrain-specific Atg7 cKO mice display
normal basal synaptic transmission but impaired LTP of the Schaffer collateral tract. Extracellular recording of field potentials was performed at
area CA1 of acutely prepared hippocampal slices from 3-month-old male CamK-Atg7 cKO mice and CamK-Atg7 cWT littermates. a, Plots of fEPSP
slope (normalized to maximal) versus stimulus intensity. There was no significant difference in baseline synaptic transmission between CamK-Atg7
cKO mice and CamK-Atg7 cWT littermates. n = 12 slices from 3 mice per genotype. b, Paired-pulse facilitation in CamK-Atg7 cKO mice. The
percent facilitation, determined by the ratio of the second fEPSP initial slope to the first fEPSP initial slope, is shown at interpulse intervals from 10
to 300 ms. n = 12 slices from 3 mice per genotype. c, Impaired LTP in CamK-Atg7 cKO mice. Stable baseline responses were recorded prior to HFS
(100 Hz HFS for 1 s) as indicated by arrow. One train of 100 Hz HFS elicited E-LTP in CamK-Atg7 cKO mice that was decreased compared with
that evoked in CamK-Atg7 cWT mice. Open squares, CamK-Atg7 cWT; Filled squares, CamK-Atg7 cKO. n = 12 slices from 3 mice per genotype.
p < 0.01 by repeated measures ANOVA. (d-e) Impaired fear memory of forebrain-specific Atg7 cKO mice. d, CamK-Atg7 cKO mice showed
significant impairment in contextual fear memory 24 h after the training. e, CamK-Atg7 cKO mice had impaired cued fear memory in the third
day. Freezing level before the cue (tone) was not altered in CamK-Atg7 cKO mice relative to CamK-Atg7 cWT littermates (‘Pre-Test’). White bars,
CamK-Atg7 cWT (n = 10); Black bars, CamK-Atg7 cKO (n = 8). *, P < 0.05. **, P < 0.01.
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We investigated whether neurodegeneration caused by
Atg7-deficiency is associated with typical pathological
hallmarks of human neurodegenerative syndromes.
Macroautophagy has previously been implicated in theclearance of various proteins implicated in human neuro-
degenerative syndromes including Alzheimer precursor
protein (APP), α-synuclein, TDP-43, tau, and huntingtin
[22-29]. However, direct in vivo evidence of an essential
role for macroautophagy in the degradation of these
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(or the APP-derived peptide fragmant β-amyloid), α-synu-
clein, or TDP-43 was detected in CamK-Atg7 cKO mouse
brain (Additional file 3a, b). However, cytoplasmic inclu-
sions in Atg7-deficient CA1 pyramidal neurons and cere-
bral cortex neurons were prominently stained with
multiple well-characterized antibodies to phospho-tau in-
cluding AT8 (epitope at Ser202/Thr205), AT100 (epitope
at Ser212/Thr214), and TG3 (epitope at Thr231/Ser235)
[30,31] (Figure 3a-c). Similarly, electron microscopic ana-
lysis confirmed TG3-positive staining in the cytoplasmic
inclusions of Atg7-deficient neurons (Figure 3d). We note
that the inclusions were not stained with other antibodies
for mature phospho-tau positive inclusions in human
pathology, AT270 (epitope at Ser181) and PHF1 (epitope
at Ser396/Ser404). Furthermore, the cytoplasmic inclu-
sions did not stain with Thioflavin S, which marks mature
NFTs in human tauopathies (Additional file 3c).
Quantitative Western blotting of forebrain extracts
revealed that phospho-tau protein epitopes were broadlyFigure 3 Phospho-tau-positive inclusions in conditional Atg7-deficien
CamK-Atg7 cKO mice. a, AT8, an antibody against phospho-tau at Ser202/T
cortical neurons, with slight background signals (asterisks) in cell nucleus, o
phospho-tau at Ser212/Thr214 residues (red, arrows), stained p62-positive i
(asterisks) in cell nucleus, of CamK-Atg7 cKO mice. Bar, 10 μm. c, TG3, an an
stained p62-positive inclusions (green) in cortical neurons of CamK-Atg7 cK
phospho-tau-positive inclusion in CamK-Atg7 cKO mice. Immunoelectron m
antibody TG3 and horseradish peroxidase staining (dark speckles; contrast t
(dashed square in left). Bars, 2 μm (left) and 500 nm (right). (e) Phospho-tau
Western blotting reveals that AT8-, AT100- or TG3-positive phospho-tau is s
fractions of CamK-Atg7 cKO brain tissue extracts. AT270- or PHF1-positive p
independent samples are presented for each genotype, as labelled at bottoincreased in forebrain tissues from CamK-Atg7 cKO
mice, whereas total tau protein appeared unaltered
(Figure 3e). Several epitopes, including AT8, AT100, and
TG3, were increased in both 0.5% TritinX-100-soluble
and insoluble brain extracts (relative to CamK-Atg7
cWT controls; Figure 3e), whereas AT180 accumulated
only in insoluble extracts, and accumulation was not
altered for AT270 and PHF1 (Figure 3e). The phospho-
tau epitope staining pattern appeared very similar in
midbrain DA neurons of Dat-Atg7 cKO mice
(Additional file 2e, Figure 4e). A similar phospho-tau
pattern has previously been suggested to represent an
early ‘pre-tangle’ state [32]; this may reflect an early
stage of non-fibrillar tau aggregation prior to its assem-
bly into paired helical filaments (PHF). Taken together,
these data implicate phospho-tau accumulation in Atg7-
deficiency-mediated neurodegeneration. However, the
phospho-tau aggregates in the context of Atg7-deficient
neurons do not replicate aspects of mature human tauo-
pathy pathology.t mice. (a-c) Phospho-tau-positive inclusions in cortical neurons of
hr205 residues (red, arrows), stained p62-positive inclusions (green) in
f CamK-Atg7 cKO mice. Bar, 10 μm. b, AT100, an antibody against
nclusions (green) in cortical neurons, with slight background signals
tibody against phospho-tau at Thr231/Ser235 residues (red, arrows),
O mice. Bar, 10 μm. (d) Immunoelectron microscopic analysis of
icroscopic analysis of inclusions using the phospho-tau-specific
o Figure. 1f). At right is a high magnification image of the inset
levels are elevated in forebrain extracts of CamK-Atg7 cKO mouse.
ignificantly increased in both 0.5% Triton X-100-soluble and -insoluble
hospho-tau and total tau [Tau1] were not changed. n = 5. Two
m.
Figure 4 GSK3β-positive inclusions in conditional Atg7-deficient mice. (a-c) GSK3β-positive inclusions in cortical neurons of CamK-Atg7 cKO
mice. a, An antibody recognizing total GSK3β (red, arrows), stained p62-positive inclusions (green) in cortical neurons of CamK-Atg7 cKO mice.
Bar, 10 μm. b, Antibodies recognizing phosphorylated, activated form of GSK3β (Tyr279/Tyr216; in red, arrows) stained p62-positive (green)
inclusions in cortical neurons of CamK-Atg7 cKO mice. Bar, 10 μm. c, An antibody recognizing phosphorylated inactivated forms of GSK3β at Ser9
residues (red, arrows), stained p62-positive inclusions (green) in cortical neurons of CamK-Atg7 cKO mice. Bar, 10 μm. (d) GSK3β levels are
elevated in the forebrain extracts of CamK-Atg7 cKO mouse. Western blotting reveals that phosphorylated forms of GSK3β (both activated Tyr216
residue and inactivated Ser9 residue) as well as total GSK3β were significantly increased in CamK-Atg7 cKO brain tissue extracts. Triangle, GSK3α.
Circle, GSK3β. n = 5 per group. (e) Summary of phosphorylation and antibody recognition sites of human tau protein. The phosphorylated sites
(Ser202/Thr205 [AT8], Thr212/Ser214 [AT100], and Thr231/Ser235 [TG3] residues) in Atg7-deficient mice are shown in red. Non-phosphorylated
sites are shown in blue. Phosphorylation sites are numbered according to the human tau protein by convention; the homologous corresponding
phosphorylation sites in the mouse tau protein are each positioned 11 amino acids towards the amino terminus.
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Atg7-deficient neurons
Given the accumulation of phosphorylated – but not
total – tau in Atg7-deficient neurons (Figure 4e), we
hypothesized that a kinase that is known to phosphoryl-
ate tau, such as GSK3β, may be altered. Immunostaining
of cortical neurons revealed dramatic re-localization of
GSK3β, including both active (epitope at Tyr216) and
inactive (epitope at Ser9) phosphorylated forms, to
phospho-tau-positive and ubiquitin/p62-positive inclu-
sions in Atg7-deficient neurons (Figure 4a-c). Western
blot analysis confirmed that total and phosphorylated
forms of GSK3α/β were increased in forebrain tissue
extracts from CamK-Atg7 cKO mice, compared to
CamK-Atg7 cWT mice (Figure 4d). Another kinase
implicated in phosphorylation of tau, CDK5, did not ap-
pear to be re-localized to the inclusions in Atg7-
deficient neurons [33] (Additional file 4d). Inclusions in
Atg7-deficient neurons stained positively for a second
microtubule-associated GSK3β substrate, phospho-
CRMP2 [34] (Additional file 4a,b). In contrast, β-Catenin,
a well-described GSK3β substrate in the context of Wnt
signaling pathway, did not appear altered in staining inAtg7-deficient neurons (Additional file 4c). Thus, accu-
mulated GSK3β in the context of Atg7-deficiency appears
to display substrate specificity, perhaps related to subcel-
lular re-localization at inclusions.
Pharmacological or genetic inhibition of phospho-tau
accumulation can rescue neuronal cell death in vivo
To examine the causality between phospho-tau and neu-
rodegeneration in the context of Atg7-deficiency, we
sought to determine whether neurons deficient in Atg7
could be effectively protected in vivo through the modu-
lation of phospho-tau production. We focused these
‘rescue’ studies on Dat-Atg7 cKO mice (rather than
CamK-Atg7 cKO mice) because the neurodegeneration
progresses more rapidly in Dat-Atg7 cKO mouse model
than CamK-Atg7 cKO mouse model, as noted above, and
the degenerative and pathological processes are restricted
to a single cell type in the Dat-Atg7 cKO mice (midbrain
DA neurons; Additional file 2a,b). Dat-Atg7 cKO mice
also displayed a very similar pathological progression to
CamK-Atg7 cKO mice with cytoplasmic ubiquitin- and
p62-positive inclusions (Additional file 2c,d) that further
stain for phospho-tau and GSK3β (Additional file 2e,f).
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a more facile and accurate quantification of the cell au-
tonomous impact of macroautophagy on the loss of ma-
ture CNS neurons.
To investigate the role of phospho-tau accumulation
in Atg7-deficiency-induced neurodegeneration, Dat-Atg7
cKO or Dat-Atg7 cWT mice were treated chronically
with a potent GSK3β/CDK5 inhibitor, Alsterpaullone
(5 mg/kg/d, i.p.) for a period of 3 weeks starting at
5-week of age [35]. Alsterpaullone can inhibit the activ-
ities of GSK3β, as well as several other tau kinases
(CDK1/2/5, GSK3α, and, to lesser extent, ERK1/2 and
PKA) to suppress tau phosphorylation (Additional file
5a) [36]. At the end of the treatment course (8-weeks of
age), pathological examination of the mice revealed that
Alsterpaullone treatment led to a significant increase in
the survival of midbrain DA neurons in Dat-Atg7 cKO
mice (24.3% increased survival, p < 0.01), whereas
Alsterpaullone-treated control Dat-Atg7 cWT mice
appeared unaltered (Figure 5a, b). In contrast, ubiquitin-
positive inclusions were unchanged in size and number in
Alsterpaullone-treated Dat-Atg7 cKO mice, whereas no
inclusions were seen in Alsterpaullone-treated Dat-Atg7
cWT mice (Additional file 5b, c). This is consistent with
the previous report that the inclusion formation and neu-
rodegeneration are independent in the context of macro-
autophagy deficiency [17]. These in vivo results are
suggesting a protective effect by phospho-tau inhibition
in the context of macroautophagy deficiency-induced
neurodegeneration. As Alsterpaullone does display some
inhibitory activity at kinases in addition to GSK3β, such
as CDK5 [36], we cannot exclude additional in vivo kinase
targets. But we note that unlike GSK3β, CDK5 did not
appear modified or re-localized in Dat-Atg7 cKO neurons
(Additional file 4d).
Next, we examined the effect of tau-deficiency [37] in
Dat-Atg7 cKO mice. We generated Dat-Atg7/tau double
cKO (DatCre/+Atg7flox/floxtau-/-) mice, and compared the
loss of midbrain DA neuron in Dat-Atg7 single cKO
(DatCre/+Atg7flox/floxtau+/+ or DatCre/+Atg7flox/floxtau+/-)
and Dat-Atg7/tau double cKO mice. The loss of mid-
brain DA neurons in Dat-Atg7 cKO mice was signifi-
cantly rescued in Dat-Atg7/tau double cKO mice at the
age of 3-month (Figure 5c,d). Again, the formation of
ubiquitin-positive inclusion was not changed in
Dat-Atg7/tau double cKO mice (Additional file 5d,e).
Consistent with the previous report that tau-deficiency
alone led to no abnormality in the brain [37,38], neither
neurodegeneration nor ubiquitin/p62-positive inclusions
was seen in the midbrain DA neurons of tau KO mice
(Figure 5c,d and Additional file 5d,e). Taken together,
these approaches support a model whereby accumula-
tion of phospho-tau contributes to neurodegeneration in
the context of macroautophagy-deficiency, whereas theformation of ubiquitin/p62-positive inclusions is inde-
pendent of phospho-tau signaling.
Discussion
Here we investigated mechanisms of neurodegeneration
downstream of Atg7-deficiency, and describe the patho-
logical accumulation of GSKβ and phospho-tau proteins.
A striking feature of neuropathology in the context of
Atg7-deficiency is the redistribution of GSK3β to inclu-
sions. We note that both GSK3β and phospho-tau are
reported to be found in inclusions in tauopathy patient
brain [39-43]. However, it is important to emphasize that
Atg7-deficiency does not appear to induce a full tauopa-
thy pathology, as not all phospho-tau epitopes are
observed (e.g., PHF1 antibody is negative, Figure 4e),
and amyloid staining with Thioflavin S, as well as elec-
tron microscopic analysis, do not support the presence
of mature NFTs. A similar phospho-tau pattern has pre-
viously been suggested to represent an early ‘pre-tangle’
pathological state [32], thought to reflect non-fibrillar
tau aggregation prior to assembly into PHFs. Such non-
fibrillar hyperphosphorylated tau, rather than mature
NFTs, may be the relevant toxic form in vivo in the con-
text of neurodegeneration and behavioral impairment
[44]. Hoozemans et al. reported phospho-tau-positive
pre-tangles with accumulation of GSK3β, ubiquitin and
p62 in postmortem specimens of AD patients [45], rem-
iniscent of pathology in Atg7-deficient neurons in vivo.
Phospho-tau pathology as seen in Atg7-deficient
animals may broadly relate to neuronal dysfunction in
neurodegeneration, as macroautophagy deficiency and
phospho-tau are commonly observed in a broad array of
neurodegenerative disorders including AD, PD, tauopa-
thy, huntington disease, amyotrophic lateral sclerosis,
and Gaucher disease [6,46-49]. Although genetic muta-
tions in ATG7 have not been described in human
disease, mutations within other components of the
macroautophagy-lysosomal pathway underlie tauopa-
thies [50], consistent with our observations in the mouse
model.
The in vivo pharmacological and genetic ‘rescue’ stud-
ies herein suggest a role for phospho-tau accumulation
in neurodegeneration downstream of Atg7-deficiency. In
contrast, prior attempts to rescue macroautophagy-
deficiency associated neurodegeneration by preventing
the formation of aggregates, by generation of double-
knockout mice deficient in Atg7 as well as p62, were un-
successful [17], suggesting that inclusion formation
per se is insufficient for degeneration. It is interesting to
note that nonetheless, p62 deletion does rescue the Atg7
deficiency-associated cell loss in hepatocytes [17], and
thus degenerative pathways downstream of macroauto-
phagy loss appear cell type-specific. Furthermore, within
the CNS, various neuronal subtypes appear to be
Figure 5 Neuroprotection of Atg7-deficient CNS neurons in vivo. (a-b) Pharmacological rescue of Atg7-deficient midbrain DA neuron loss by
systemic injection of the selective GSK3β/CDK5 inhibitor Alsterpaullone. Five-week-old mice were dosed daily with 5 mg/kg Alsterpaullone by
intraperitoneal injection for a 3-week period prior to analysis. TH-positive DA neuron loss was suppressed in Alsterpaullone-treated Dat-Atg7 cKO
mice, whereas Alsterpaullone-treated control Dat-Atg7 cWT mice were unaffected. b, Quantification of TH-positive DA neuron number.
**, P < 0.01. n = 5 - 6 / group. (c-d) Genetic rescue of DA neuron death in Atg7-deficient mice by secondary tau deletion. Immunostaining for
TH-positive DA neurons at 3-month of age revealed significant protection of midbrain DA neurons from neurodegeneration in Atg7 single
KO mice (Dat-Atg7 cKO) relative to controls (Dat-Atg7/tau double cWT). d, Quantification of TH-positive DA neuron number. **, P < 0.01.
n = 4 - 6 / group. (e) Proposed model of phospho-tau and GSK3β regulation by macroautophagy. In physiological or pre-pathological states, basal
macroautophagy regulates endogenous levels of phospho-tau and GSK3β (dashed square). In pathological states or with aging, macroautophagy
is impeded, and phospho-tau and GSK3β are accumulated. These in turn lead to feedback induction of the macroautophagy pathway,
although such feedback is ineffective in late-stage disease or in knockout mice.
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Purkinje neurons deficient in Atg7 display axonal swel-
lings and are rapidly lost [51]. TH-positive midbrain DA
neurons display axonal dystrophy and degeneration, ubi-
quitin/p62-positive inclusions, and delayed cell loss and
locomotor dysfunction [52]. Although tau pathology
was not investigated in these other models, staining for
the Parkinson’s disease associated proteins α-synuclein
and leucine rich repeat kinase-2 (LRRK2) was reported
in Atg7-deficient DA neurons [52]. We failed to detect
evidence of α-synuclein accumulation in our analysis of
either midbrain DA neuron-selective or forebrain
neuron-selective Atg7-deficient mice detailed above
(data not shown). Such discrepancies may reflect differ-
ences in the selectivity or timing of the CRE-mediated
deletion strains used in the different studies, or selective
sensitivity to macroautophagy loss across distinct
neuron types. We note that phospho-tau pathology wasapparent in the context of either midbrain DA neuron-
selective or forebrain neuron-selective Atg7-deficiency.
The molecular basis of GSK3β and phospho-tau accumu-
lation in Atg7-deficient neurons remains to be elucidated.
We cannot exclude the possibility that GSK3β accumula-
tion is a secondary effect of phospho-tau accumulation. A
recent study described intracellular redistribution of GSK3β
to multivesicular bodies, albeit in the context of Wnt path-
way modulation [53]. As multivesicular bodies directly as-
sociate with the macroautophagy machinery, it is possible
that GSK3β degradation is selectively modified with macro-
autophagy loss [54]. Although GSK3β is a strong candidate
for the relevant upstream kinase, we hypothesize the
involvement of other kinase pathways, particularly given
the multiple targets of the pharmacological kinase in-
hibitor used, Alsterpaullone. Furthermore, Alsterpaullone-
mediated protection may be mediated through targets in
addition to tau, which would be of further interest.
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lating the metabolism of phospho-tau proteins at physio-
logical or pre-pathological state (Figure 5e). In the
context of macroautophagy loss, GSK3β and phospho-
tau are accumulated, reminiscent of early pathology that
precedes human tauopathy. It is interesting to note that
both GSK3β and tau are believed to be potent upstream
regulators of macroautophagy [55-58]. We hypothesize
that this may reflect a feedback loop, where defective
macroautophagy leads progressively to more accumulation
of phospho-tau and GSK3β, and in turn the accumulated
phospho-tau and GSK3β both induce macroautophagy
activity. Initially such feedback may be effective, although
the accumulated proteins form inclusions. But once
macroautophagy deficiency is complete, as in late-stage
disease or in knockout mice, this feedback would be inef-
fective. Thus, such a feedback circuit may be an important
pathway to rejuvenate the macroautophagy pathway,
which is known to wane with aging [59].
Conclusions
Atg7 cKO in mouse forebrain neurons led to an age-
dependent neurodegeneration with ubiquitin/p62-posi-
tive and phospho-tau/GSK3β inclusions, but not the full
pathological features of NFTs in tauopathy. Pharmaco-
logical or genetic inhibition of tau phosphorylation
in vivo successfully rescued neurodegeneration in the
context of macroautophagy-deficiency. As GSK3β and
tau are also upstream inducers of macroautophagy, this
implicates a negative feedback loop in human pathology.
Methods
Animal
CamK-Cre transgenic mice, DatCre/+ mice, Atg7flox/flox
mice, hAPP-Tg and tau KO mice, used in this study
were generated previously [19,20,37,60-62]. CamK-Cre
Tg and tau KO mice were purchased from Jackson La-
boratories. All animals were maintained in the animal fa-
cility of the Columbia University Medical Center.
Experimental protocols were approved by the Institu-
tional Animal Care and Use Committee. Genomic DNA
extracted from mouse tails was amplified by PCR for
genotyping using standard methods. The PCR primers
are the followings: 5’-AGA TGT TCG CGA TTA TC-3’,
5’-AGC TAC ACC AGA GAC GG-3’ for Cre transgene;
5’-TGC TCT GTG AAC TGC CCT GTT T-3’, 5’-TGT
TCC TGT GCA CTG CCT CAT T-3’ for Atg7 wild-type
allele; 5’-CTT GGG TGG AGA GGC TAT TC-3’, 5’-
AGG TGA GAT GAC AGG AGA TC-3’ for Atg7 floxed
allele.
Histology
Mice were perfused and fixed in 4% paraformaldehyde
and post-fixed at 4°C overnight, 50 μm coronal brainsections were generated using a vibratome. The sections
were blocked with PBS containing 5% normal donkey
serum [NDS], 0.2% Triton X-100 [Tx] for 1 h, and incu-
bated with the solution (PBS, 1% NDS, 0.2% Tx) con-
taining primary antibody at 4°C overnight. The following
antibodies were used; anti-TH (P60101, Pel-Freez), anti-
TuJ1 (MMS-435P, COVANCE), anti-MAP2 (AB5622,
Millipore), anti-cleaved caspase-3 [Asp175] (#9661,
Millipore), anti-active caspase-3 (AB3623, Cell Signaling
Technology), anti-ubiquitin (Sigma-Aldrich), anti-p62
(03-GP62-C, American Research Products), anti-Aβ
[4G8] (SIG39200, COVANCE), anti-Aβ [6E10]
(SIG39300, COVANCE), anti-αSynuclein (610786, BD
Bioscience) (AB5038, Millipore) (ab1903, ab24715,
Abcam), anti-phosph-tau TG3 and PHF1 (gifts from Dr.
Peter Davies, Alberts Einstein College of Medicine),
anti-phospho-tau AT8, AT100, AT180, and AT270
(Pierce), anti-total GSK3β (#9315, Cell Signaling Tech-
nology), anti-phospho-GSK3α/β [Y279/Y216] (ab52188,
Abcam), anti-phospho-GSK3β [S9] (ab30619, Abcam),
anti-total CRMP2 (#9393, Cell Signaling Technology),
anti-phospho-CRMP2 [T514] (#9397, Cell Signaling
Technology), anti-Cdk5 (MAB5410, Millipore), anti-p35/
25 (#2680, Cell Signaling Technology), anti-β-catenin
(#9581, 9587, Cell Signaling Technology), and anti-
β-catenin (#610154, BD Biosciecnes). For secondary
detection, Cy3- or FITC-conjugated antibodies were
incubated for 1 h (Jackson ImmunoResearch). Photo-
graphs were taken using a Zeiss LSM 510 Meta confocal
microscope.
Neuron counting
To obtain neuronal cell count, 50 μm coronal brain sec-
tions were made using a vibratome. In order to count
CA1 neurons, the first 30 sections from the rostral
hippocampus were stained with rabbit anti-MAP2 anti-
body (AB5622, Millipore) at a dilution of 1:500, as well
as NeuroTraceTM Fluorescent Nissl stain (N21480, Invi-
trogen). MAP2-positive neurons were visualized using a
Cy3-conjugated secondary antibody (Jackson ImmunoR-
esearch). MAP2 and Nissl double-positive neurons in
the CA1 regions were counted manually. In order to
count TH-positive neurons, sections covering the entire
substantia nigra (25-30 sections / mouse) were stained
with sheep anti-TH antibody (P60101, Pel-Freez) at a di-
lution of 1:250. TH-positive neurons were visualized
using the ABC Kit (PK6106, Vector Laboratories) and
DAB (SK4100, Vector Laboratories). TH-positive neu-
rons in the substantia nigral regions were counted
manually under the light microscope.
Electron microscopy
Electron microscopic analysis was as described [61].
Anesthetized mice were perfused and fixed in PBS
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hyde. The brains were post-fixed at 4°C for 2 h, and the
80 μm vibratome sections were made. The sections were
treated in 1% osmium tetroxide, then dehydrated in pure
ethanol and infiltrated overnight with Epon 812. Epon
was polymerized at 60°C for 24 h, cooled and embedded
in a larger Epon capsule. Ultrathin sections were cut
with an MT5000 ultramicrotome, stained with uranyl
acetate and lead citrate. Images were taken with a JOEL
100S Electron Microscope (JOEL USA).
Tissue fractionation
Preparation of soluble and insoluble fractions was per-
formed as described with some modifications [14]. Cor-
tical and hippocampal tissues from mouse brains were
homogenized in 5× volume of ice-cold 0.25M sucrose
buffer (50mM Tris-HCl [pH7.6]) containing protease
inhibitors (P8340, Sigma) and phosphatase inhibitors
(#78420, Thermo Scientific). The homogenized tissues
were centrifuged at 500× g for 10 min at 4°C. The super-
natants were lysed with an equal volume of cold sucrose
buffer containing 1% Triton X-100. The lysates were
centrifuged at 13,000× g for 15 min at 4°C. The superna-
tants contained the soluble fraction. The pellets were
resuspended in 1% SDS in PBS (insoluble fraction). Both
fractions were subjected to standard Western Blotting
analysis. The antibodies used here are: anti-phospho-tau
AT8, AT100, AT180, AT270, TG3 and PHF1, anti-Tau1
and anti-Actin (ab3280, Abcam). Horseradish peroxidase-
conjugated secondary antibodies (Jackson ImmunoRe-
search) and SuperSignal West Pico or Dura (#34077,
34075, Pierce) were used for detection.
Electrophysiology
Brains from CamK-Atg7 cWT and cKO mice littermates
(~12 weeks of age) were quickly removed and transverse
hippocampal slices (400 μm) were isolated with a Leica
VT1200 Vibratome (Leica, Bannockburn, IL), and placed
in ice-cold cutting solution (CS: 110 mM Sucrose, 60
mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 28 mM
NaHCO3, 0.5 mM CaCl2, 7 mM MgCl2, 5 mM Glucose,
0.6 mM Ascorbate. Slices were placed in an interface
chamber (Scientific Systems Design, Mississauga,
Ontario, Canada) and maintained at 32°C in ACSF (2
ml/min) containing 125 mM NaCl, 2.5 mM KCl, 1.25
mM NaH2PO4, 25 mM NaHCO3, 25 mM D-glucose, 2
mM CaCl2, and 1 mM MgCl2. All solutions were con-
stantly caboxygenated with 95% O2 + 5% CO2. Slices
were allowed to recover for 120 min on the electrophysi-
ology rig prior to experimentation. Bipolar stimulating
electrodes (92:8 Pt:Y) were placed at the border of area
CA3 and area CA1 along the Schaffer-Collateral path-
way. ACSF-filled glass recording electrodes (1–3 MΩ)
were placed in stratum radiatum of area CA1. Basalsynaptic transmission was assessed for each slice by ap-
plying gradually increasing stimuli (0.5–15V), using a
stimulus isolator (A-M Systems, Carlsborg, WA) and de-
termining the input:output relationship. All subsequent
stimuli applied to slices was equivalent to the level ne-
cessary to evoke a fEPSP that was ~40% of the maximal
initial slope that could be evoked. Synaptic efficacy was
continuously monitored (0.05 Hz). Sweeps were aver-
aged together every 2 min. fEPSPs were amplified (A-M
Systems Model 1800) and digitized (Digidata 1440, Mo-
lecular Devices, Sunnyvale, CA) prior to analysis
(pClamp, Molecular Devices, Sunnyvale, CA). Stable
baseline synaptic transmission was established for 30
min. Slices were given high-frequency stimulation (HFS)
to induce long-term potentiation (LTP) using one train
of 100 Hz for one second. Stimulus intensity of the HFS
was matched to the intensity used in the baseline
recordings. fEPSP initial slopes from averaged traces
were normalized to those recorded during baseline.
Two-way RM-ANOVA were used for electrophysio-
logical data analysis with p < 0.05 as significance criteria.Fear conditioning
10-13-mon-old male CamK-Atg7 cWT or CamK-Atg7
cKO mice were used (n = 8 - 10). The mice were placed
in a conditioning chamber (Med Associates) for 2 min
before the onset of a tone (conditioned stimulus) (30 s,
85 dB sound at 2800 Hz) and conditioned by a single
electrical foot shock (0.45 mA) in the last 2 s. The mice
were left in the chamber for another 30 s and placed
back into their home cage. Contextual fear learning was
measured in the same chamber 24 h after the training
by monitoring the freezing for 5 min without electrical
shock. Cued fear learning was measured 24 h after the
contextual testing. The mice were placed in a novel
chamber for 2 min (pre-conditioning). After that, the
mice were exposed to the conditioned stimulus for 3
min, and the freezing was monitored. Freezing behavior
was scored using FreezeView software (Med Associates
Inc.).Drug injection
Five-week-old Dat-Atg7 cWT and Dat-Atg7 cKO mice
were treated with Alsterpaullone (A1136, A.G. Scientific)
[35]. The drug was dissolved in saline containing 20%
DMSO/ 25% Tween80, sonicated, and injected intraperi-
toneally at a dose of 5 mg/kg every day for 3 weeks.
After the final injection, the mice were perfused and
processed for histological analyses. We used Dat-Atg7
cWT mice as controls for Dat-Atg7 cKO mice, to ad-
dress potential phenotypes due to Cre transgene inserted
at the DAT locus [62].
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All comparisons between groups were made using the
Mann-Whitney U-test (for two samples) or non-
repeated measures ANOVA (for multiple samples). The
values are expressed as the means ± S.E. A p value less
than 0.05 is considered significant.Additional files
Additional file 1: Intracellular ubiquitin and p62 positive inclusions
in 6-month-old CamK-Atg7 cKO mice. Ubiquitin-positive inclusions are
almost completely overlapped with p62-positive inclusions in the
cerebral cortex of CamK-Atg7 cKO mice. Ubiquitin/p62-positive inclusions
were already seen at 2-month-old Atg7 cKO mice. Bar, 10 μm.
Additional file 2: Progressive neurodegeneration in midbrain DA
neuron-specific Atg7-deficient (Dat-Atg7 cKO) mice. (a-b) Progressive
loss of DA neurons in Dat-Atg7 cKO mice. a, Representative midbrain
sections stained with polyclonal antibody specific for TH.Bar, 250 μm. b,
Quantification of TH-positive DA neuron number as in (a). White bars,
Dat-Atg7 cWT. Black bars, Dat-Atg7 cKO. n = 3 –7 for each group. **,
P<0.01. (c-d) Cytoplasmic and dendritic inclusions in Dat-Atg7 cKO mice.
Ubiquitin-positive (c, red) and p62/SQSTM1-positive (d, red) inclusions
were present in TH-positive DA neurons (green) of 1-month-old Dat-Atg7
cKO mice, but were never seen in control Dat-Atg7 cWT mice. Bars, 10
μm. (e) Phospho-tau-positive inclusions in TH-positive DA neurons in Dat-
Atg7 cKO mice. Phospho-tau specific antibodies (red), AT8, AT100, and
TG3, stained inclusions (arrows) in the soma and dendrites of TH-positive
DA neurons (green) in Dat-Atg7 cKO mice. AT8, tau phosphorylated at
Ser202/Thr205. AT100, tau phosphorylated at Ser212/Thr214. TG3, tau
phosphorylated at Thr231/Ser235. Bar, 10 μm. (f) GSK3β-positive
inclusions in TH-positive DA neurons in Dat-Atg7 cKO mice. Antibodies
recognizing total, activated form (Tyr279/Tyr216), and inactivated form
(Ser9) of GSK3β (red), stained the inclusions (arrows) in TH-positive DA
neurons (green) in Dat-Atg7 cKO mice. Bar, 10 μm.
Additional file 3: APP/Aβ-negative, α-Synuclein-negative, and
Thioflavin S-negative inclusions in CamK-Atg7 cKO mice. (a) The
ubiquitin-positive inclusions (green) in 1-year-old CamK-Atg7 cKO mice
did not contain mouse Aβ (red) (left). 4G8, monoclonal antibody to
amino acid residues 17-24 of Aβ, was used. Ten-month-old transgenic
mice bearing a mutant form of human APP (K670N/M671L/V717F, J20
line) were used as positive control for Aβ plaque staining (right). Similar
negative results were obtained by 6E10, another antibody to amino acid
residues 1-16 of Aβ (data not shown). Bars, 10 μm. (b) The ubiquitin-
positive inclusions (green) in 1-year-old CamK-Atg7 cKO mice did not
contain mouse α-Synuclein (red). Four different anti-α-synuclein
antibodies were used for the double staining. None of four anti-α-
synuclein antibodies could detect any positive signals (red) in ubiquitin-
positive inclusions (green). Bar, 10 μm. (c) Ubiquitin-positive inclusions
(red) in 1-year-old CamK-Atg7 cKO mice were negative for Thioflavin S
staining (green, left). Thioflavin S stains plaques from β-amyloid and
neurofibrillary tangles. Ten-month-old J20 APP transgenic mice were
used as positive control for Thioflavin S staining (right). Bars, 20 μm.
Additional file 4: Immunohistochemical analyses of Atg7-deficient
neurons. (a-b) CRMP2-positive inclusions in cortical neurons in CamK-
Atg7 cKO mice. a, An antibody recognizing total CRMP2 (red), stained
p62-positive inclusions (green) in cortical neurons of CamK-Atg7 cKO
mice. Bar, 10 μm. b, An antibody recognizing phosphorylated forms of
CRMP2 at Thr514 residues (red), stained p62-positive inclusions (green) in
cortical neurons of CamK-Atg7 cKO mice. Bar, 10 μm. (c) β-Catenin-
negative inclusions in TH-positive DA neurons in Dat-Atg7 cKO mice.
Antibodies recognizing β-Catenin (red) did not stain the inclusions in TH-
positive DA neurons (green) in Dat-Atg7 cKO mice. Bar, 10 μm. (d) CDK5-
negative inclusions in TH-positive DA neurons in Dat-Atg7 cKO mice.
Antibodies recognizing CDK5 (red) did not stain the inclusions in TH-
positive DA neurons (green) in Dat-Atg7 cKO mice. Bar, 10 μm.Additional file 5: Neuroprotection of Atg7-deficient CNS neurons
in vivo. (a) Alsterpaullone can reduce phospho-tau accumulation in the
context of macroautophagy inhibition. N2a cells were treated with 1 μM
Alsterpaullone in the context of 100 μM chloroquine treatment for 24 h.
Cells were lysed in RIPA buffer and subjected to standard Western
blotting analysis. Phospho-tau levels were detected by AT8 antibody.
(b-c) Ubiquitin-positive inclusion formation was unaffected by systemic
injection of Alsterpaullone in the context of Dat-Atg7 cKO mice. Bar, 10
μm. c, Quantification of ubiquitin-positive inclusion number per TH-
neuron in Dat-Atg7 cKO mice. No inclusions were observed in Dat-Atg7
cWT mice. n > 60 neurons per genotype. (d-e) Ubiquitin-positive
inclusion formation (red) was not changed in TH-positive DA neurons
(green) of Dat-Atg7/tau double cKO mice relative to Dat-Atg7 cKO mice.
No ubiquitin-positive inclusions were detected in tau KO mice. Bar, 10
μm. e, Quantification of ubiquitin-positive inclusion number per TH-
neuron in Dat-Atg7/tau double cKO mice. n > 60 neurons per genotype.
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